CYSTIC FIBROSIS

Sildenafil (Viagra) corrects F508-CFTR location in nasal epithelial cells from patients with cystic fibrosis

R L Dormer¹, C M Harris¹, Z Clark¹, M M C Pereira¹, I J M Doull², C Norez³, F Becq³, M A McPherson¹

¹ Department of Medical Biochemistry and Immunology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK
² Department of Child Health, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK
³ Institut de Physiologie et Biologie Cellulaires, UMR 6187, CNRS, Université de Poitiers, France

Correspondence to:
Correspondence to:
Dr R L Dormer
Department of Medical Biochemistry and Immunology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK; dormer{at}cardiff.ac.uk

Background: Most patients with cystic fibrosis (CF) have a F508 mutation resulting in abnormal retention of mutant gene protein (F508-CFTR) within the cell. This study was undertaken to investigate F508-CFTR trafficking in native cells from patients with CF with the aim of discovering pharmacological agents that can move F508-CFTR to its correct location in the apical cell membrane.

Method: Nasal epithelial cells were obtained by brushing from individuals with CF. CFTR location was determined using immunofluorescence and confocal imaging in untreated cells and cells treated with sildenafil. The effect of sildenafil treatment on CFTR chloride transport function was measured in CF15 cells using an iodide efflux assay.

Results: In most untreated CF cells F508-CFTR was mislocalised within the cell at a site close to the nucleus. Exposure of cells to sildenafil (2 hours at 37°C) resulted in recruitment of F508-CFTR to the apical membrane and the appearance of chloride transport activity. Sildenafil also increased F508-CFTR trafficking in cells from individuals with CF with a single copy F508 (F508/4016ins) or with a newly described CF trafficking mutation (R1283M).

Conclusions: The findings provide proof of principle for sildenafil as a F508-CFTR trafficking drug and give encouragement for future testing of sildenafil and related PDE5 inhibitors in patients with CF.

Keywords: cystic fibrosis; sildenafil (Viagra); genetics

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2005 60: 1a. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Clarke, L. L. (2008). Phosphodiesterase 5 Inhibitors and Cystic Fibrosis: Correcting Chloride Channel Dysfunction. Am. J. Respir. Crit. Care Med. 177: 469-470 [Full Text]  
• Lubamba, B., Lecourt, H., Lebacq, J., Lebecque, P., De Jonge, H., Wallemacq, P., Leal, T. (2008). Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 177: 506-515 [Abstract] [Full Text]  
• Robert, R., Carlile, G. W., Pavel, C., Liu, N., Anjos, S. M., Liao, J., Luo, Y., Zhang, D., Thomas, D. Y., Hanrahan, J. W. (2008). Structural Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect. Mol. Pharmacol. 73: 478-489 [Abstract] [Full Text]  
• Poschet, J. F., Timmins, G. S., Taylor-Cousar, J. L., Ornatowski, W., Fazio, J., Perkett, E., Wilson, K. R., Yu, H. D., de Jonge, H. R., Deretic, V. (2007). Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L712-L719 [Abstract] [Full Text]  
• (2006). Poster presentations. Thorax 61: ii57-ii133 [Full Text]  
• Moeller, A, Horak, F Jr, Lane, C, Knight, D, Kicic, A, Brennan, S, Franklin, P, Terpolilli, J, Wildhaber, J H, Stick, S M (2006). Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis. Thorax 61: 514-520 [Abstract] [Full Text]  
• Urquhart, D S, Montgomery, H, Jaffe, A (2005). Assessment of hypoxia in children with cystic fibrosis. Arch. Dis. Child. 90: 1138-1143 [Abstract] [Full Text]